Navigation Links
Biotech Industry Showing Resilience Despite Challenging Conditions
Date:4/28/2010

The end goal in product development is no longer marketing approval but payor acceptance. Companies need to invest early in pharmacoeconomic analysis to inform R&D decisions.  
  • Collaborating creatively. The report identifies several innovative partnering structures. Companies' use of creative partnering approaches could free them from turbulent public markets and give them much-needed resources.
  • Developing differentiating assets. There are fewer potential buyers and they are distracted and have fewer resources. To attract partners, biotech firms need to demonstrate what truly differentiates their products or platforms.

  • Key regional findings

    United States

    • The US industry's net income skyrocketed from about US$400 million in 2008 to a record US$3.7 billion in 2009.  The improvement in industry profitability was driven by revenue growth, cost cutting and a change in the accounting rules for acquisitions. The 2009 figures exclude the net income of Genentech, which was acquired by Roche.
    • Revenues of US public companies fell to US$56.6 billion in 2009, a 13% drop compared to 2008. When adjusting for the acquisition of Genentech, industry revenues would have instead increased by 9.5%, comparable to 2008 industry growth.
    • The value of merger and acquisition (M&A) transactions involving US-based biotech companies (excluding the Roche-Genentech transaction) decreased by half in 2009 to a total of US$14.1 billion. Only three transactions had a value in excess of US$1 billion.
    • Total US capital raised by the industry increased by 39% in 2009 to an aggregate of '/>"/>

    SOURCE Ernst & Young
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Immunovo BV- A New Biotechnology Company is Announced
    2. Maryland Biotechnology Center Supports $270,000 in MIPS Projects
    3. Reportlinker Adds Future of Red Biotechnology in China
    4. Oncolytics Biotech(R) Inc. Completes Patient Enrollment in Phase I Portion of U.S. Phase I/II Recurrent Malignant Gliomas Clinical Trial
    5. MedeFile Adds International Biotech Expert to Advisory Board
    6. Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results
    7. Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech
    8. Zenith Biotech Introducing Novel StemQ(R) Hepatic and Neural Models for Use in Drug Discovery, Metabolism and Toxicology Studies, at The 49th Annual Meeting and ToxExpo In Salt Lake City, Utah, March 7-11, 2010, Booth #136
    9. UC San Diegos Biotech Demystified Program Offers Science Basics for Industry Leaders
    10. Global Nanobiotechnology Market to Reach $4.94 Billion by 2015, According to New Report by Global Industry Analysts, Inc.
    11. Predicted Second Wave of Biotech Growth and Development Begins
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/14/2014)... 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology ... therapies addressing major unmet medical needs using RNA-targeted ... of Allowance from the United States Patent and ... (sd-rxRNA®), for the treatment of fibrosis. The patent ...
    (Date:1/14/2014)... OTTAWA, Ontario , Jan. 14, 2014   Kinaxis ®, ... ( SCM ) and sales and operations planning ( S&OP ... the Biomanufacturing Summit , which will be held at ...  At the conference, join Kinaxis customer Elisabeth Kaszas , ...
    (Date:1/14/2014)... Kerr Corporation, a leading manufacturer of innovative dental ... about dual arch impressions on its dental blog. ... blog entry serves up a list of tips to help ... by Dr. David Little as he crafts a porcelain crown ...
    (Date:1/14/2014)... 2014 Independent publisher Bitingduck Press, with ... Canada, has big ideas for 2014 in production and ... are to produce high-quality, low-cost, DRM-free ebooks and to ... , The first major development will be bookstore ...
    Breaking Biology Technology:RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2
    ... the Netherlands, February 24 ,Amsterdam Molecular Therapeutics (Euronext: AMT), a leader ... the year of 2008. , Highlights, ... delay of the announced, filing date ... - Positive clinical data on GlyberaTM, ...
    ... SPRINGS, Colo., Feb. 23 The National Academy of ... 2009 finds deficiencies in the nation,s forensic science system ... The report also calls for the development of accreditation ... a code of ethics for experts in all aspects ...
    ... 23 Texcel Medical, LLC, a full service ... company, has announced the appointment of Barry ... functions at Texcel Medical , which helps ... infrastructure and expertise they need to accelerate the ...
    Cached Biology Technology:Amsterdam Molecular Therapeutics Reports Full Year Results 2008 2Amsterdam Molecular Therapeutics Reports Full Year Results 2008 3Strengthening Forensic Toxicology in the United States: The American Board of Forensic Toxicology Response to the National Academy of Sciences Recommendations 2Texcel Medical Appoints Barry Smith as President, CEO 2
    (Date:7/9/2014)... that can attack soybean crops, why would charcoal rot ... University of Illinois scientists cite the earth,s changing climate ... the fungus that causes charcoal rot. , Fungi may ... Macrophomina phaseolina , the fungus that causes charcoal ... the climate continues to change and we see more ...
    (Date:7/9/2014)... shows that the population is 3.79 million breeding ... Adlie penguins have long been considered a key ... of climate change and fishing in the Southern ... from Stony Brook University and University of Minnesota ... monitoring of Adlie penguins across their entire breeding ...
    (Date:7/9/2014)... candidate developed by researchers at the NIH,s ... and its collaborators to treat sickle cell ... BioScience business. The drug candidate, Aes-103, is ... underlying molecular mechanism of sickle cell disease. ... activities required for regulatory approval and commercialization. ...
    Breaking Biology News(10 mins):Climate change provides good growing conditions for charcoal rot in soybeans 2Climate change provides good growing conditions for charcoal rot in soybeans 3New study finds that Adélie penguin population is on the rise 2New study finds that Adélie penguin population is on the rise 3First drug candidate from NIH program acquired by biopharmaceutical company 2First drug candidate from NIH program acquired by biopharmaceutical company 3First drug candidate from NIH program acquired by biopharmaceutical company 4
    ... with intellectual and developmental disabilities living in family ... routine dental care than those living in institutions, ... associate professor Catherine Binkley, D.D.S., Ph.D. These individuals ... to have poor oral hygiene, increased decay and ...
    ... shows that following a vegetarian diet and exercising at least ... in African Americans, who are twice as likely to be ... "These findings are encouraging for preventing type 2 diabetes ... disease than other populations," said Serena Tonstad, MD, a professor ...
    ... called "the trots," "Montezuma,s Revenge," "the runs" and worse. But ... a medicine that could go straight to the offending bacteria ... come true if work by Texas A&M University scientists stays ... Station. A "medicine that grows" is how the phage ...
    Cached Biology News:UofL researcher to develop oral health plan for those with IDD 2Vegetarian diet, physical activity protect against diabetes in black population, study shows 2Texas A&M center confronts antibiotic crisis with potential new bacterial treatment 2Texas A&M center confronts antibiotic crisis with potential new bacterial treatment 3Texas A&M center confronts antibiotic crisis with potential new bacterial treatment 4
    ...
    These 22x40mm rectangular No.1 Corning cover glasses are made from No. 0211 zinc titania glass and are 0.16 to 0.19mm thick. • Approx. Pcs Oz : 73...
    ... Experion software, PC, is used to ... data obtained from the Experion automated ... in electropherogram and simulated gel views ... calculations in a Results table. This ...
    ...
    Biology Products: